New Research on Satellos Bioscience Inc. (MSCL-TSXV/MSCLF-OTCQB)

An Executive Informational Overview (EIO) is now available on Satellos Bioscience Inc., a biotechnology company dedicated to developing life-changing medicines to treat degenerative muscle conditions. The 62-page report details the Company's business, its strategy, market opportunities, competition, financials, risks, and more. It is available for download below.

Snapshot

Satellos Bioscience Inc. (“Satellos” or “the Company”) is a biotechnology company dedicated to developing life-changing medicines to treat degenerative muscle conditions. The Company’s scientists have discovered what could possibly be a previously unrecognized root cause of skeletal muscle degeneration, which may transform how muscle disorders are treated.

Satellos’ scientific founder, Dr. Michael Rudnicki, is a thought leader who discovered and has shown how muscle stem cells regulate muscle repair and growth throughout life. He has demonstrated how defects in a process known as stem cell “polarity”, which controls how muscle stem cells divide to create muscle progenitor cells, lead to a failure of muscle regeneration in patients with Duchenne muscular dystrophy (DMD)—a rare genetic disorder of progressive muscular weakness that affects boys almost exclusively. As a result of this ongoing inability to produce sufficient numbers of new muscle cells, the muscles of individuals living with Duchenne are unable to keep up with and repair the continuous and accumulating damage to their muscles.

Satellos is developing a small molecule oral therapeutic intended to correct muscle stem cell polarity and restore the body’s innate muscle repair and regeneration process. This unique therapeutic approach could prove to be a disease modifying treatment for patients with Duchenne as well as other muscular dystrophies. To expand its programs into other degenerative muscle conditions or disorders, Satellos has created MyoReGenX™, a proprietary discovery platform, which the Company utilizes to identify disease situations where deficits in muscle stem cell polarity and regeneration occur and are open to therapeutic treatment.

Key Points of Satellos Bioscience Inc.

• Duchenne affects an estimated 1 in 4,000 live male births worldwide per year and is 100% fatal.
  
  
• Current Duchenne treatment approaches share one common aspect—they are all focused on existing muscle fibers and attempting to lessen the impact of muscle damage that has already occurred. This includes both standard of care corticosteroid treatment, or more recent genetic approaches, such as exon skipping, with Exondys 51 approved in the U.S. and indicated for patients with an exon 51 mutation (which is 12% of Duchenne patients), or gene therapy where Elevidys received U.S. FDA approval in June 2023 for the treatment of pediatric patients through the ages of 4 through 5 (only).
  
  
• Satellos is focused on restoring, repairing, and regenerating muscle fibers. Based on the unique mechanism of action of its drug candidates, the Company believes its approach may have applicability across a broad range of degenerative conditions, from lethal genetic diseases to age-related muscle loss—areas where the medical need for new treatments is significant.
  
  
• The Company holds numerous issued and pending patents related to the manipulation, modulation, and use of muscle stem cells for experimental and therapeutic purposes, including four patent families, which represent core intellectual property for Satellos.
  
  
• The Company recently raised Cdn$55 million from healthcare-focused institutional investors to advance its lead drug candidate towards an IND filing in mid-2024 and bolstered its senior management team to support this objective. 
  
  
• As of June 30, 2023, Satellos had cash and cash equivalents of Cdn$48.7 million, providing a cash runway through 2025.
  
  

*******************************************

Visit our Corporate Profile and Investment Highlights pages

for the latest research on Satellos Bioscience Inc.

*******************************************